Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. En savoir plus sur Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. En savoir plus sur Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy.
Resting energy expenditure in the risk assessment of anticancer treatments. En savoir plus sur Resting energy expenditure in the risk assessment of anticancer treatments.
Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 Study. En savoir plus sur Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 Study.
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer. En savoir plus sur Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer.
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. En savoir plus sur Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. En savoir plus sur Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. En savoir plus sur Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. En savoir plus sur Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.